GALT

Galectin Therapeutics Inc.

Price Chart

Latest Quote

$2.80

-0.03 (-0.88%)

Current Price

Previous Close	$2.83
Open	$2.82
Day High	$2.98
Day Low	$2.77
Volume	260,635

Fetched: 2026-06-23T13:28:22

Stock Information

Shares Outstanding	65.86M
Total Debt	$138.70M
Cash Equivalents	$14.11M
Net Income	$-26.44M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$205.47M
EPS (TTM)	$-0.41
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$311.19M
Income	$-26.44M
Book/sh	$-2.01
Cash/sh	$0.21
Employees	9

Financial Ratios

Quick Ratio	1.93
Current Ratio	2.15

Returns & Margins

ROA

-80.40%

Ownership

Insider Ownership	29.09%
Institutional Ownership	21.17%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.86
PEG	-36.15
P/B	-1.55

Analyst Data

Recommendation	none
Target Price	$11.00

Technical Indicators

SMA20	$2.60
SMA50	$2.42
SMA200	$3.73
RSI	80.17
ATR	0.2371

Shares Float	47.19M
Short Float	18.26%
Short Ratio	21.30
Volatility	0.49
Rel Volume	7.70

Performance History

Week	+19.08%
Month	+23.81%
Quarter	+9.09%
6 Months	-49.35%
YTD	-22.96%
Year	+28.93%
3 Years	+113.70%
5 Years	-10.86%
10 Years	+101.29%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-23	$3.12	3,792,389
2026-06-22	$2.80	260,600
2026-06-18	$2.83	336,700
2026-06-17	$2.77	266,200
2026-06-16	$2.64	382,800
2026-06-15	$2.62	276,500
2026-06-12	$2.67	282,100
2026-06-11	$2.61	304,600
2026-06-10	$2.38	263,300
2026-06-09	$2.41	294,900
2026-06-08	$2.40	193,100
2026-06-05	$2.33	215,800
2026-06-04	$2.38	111,400
2026-06-03	$2.35	226,100
2026-06-02	$2.42	280,200
2026-06-01	$2.61	315,300
2026-05-29	$2.52	282,400
2026-05-28	$2.57	354,200
2026-05-27	$2.70	424,800
2026-05-26	$2.79	982,700

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

📰 Latest News

GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial

Stocktwits • 2026-06-23T17:47:24Z

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

Zacks • 2026-04-03T16:00:03Z

Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps

MarketBeat • 2026-03-17T02:34:43Z

Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders

Simply Wall St. • 2026-01-22T14:18:01Z

Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line

MT Newswires • 2025-12-19T14:50:42Z

Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong Financials

Insider Monkey • 2025-09-23T23:21:53Z

Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are individual investors with 54% stake, while 21% is held by insiders

Simply Wall St. • 2025-08-15T13:38:44Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$7,329,000	$5,540,000	$2,792,000	$1,033,000
Total Expenses	$20,085,000	$42,433,000	$38,072,000	$38,352,000
Other Income Expense	$-3,548,000	$588,000	$-432,000	$557,000
Net Non Operating Interest Income Expense	$-7,203,000	$-5,202,000	$-2,562,000	$-981,000
Interest Expense Non Operating	$7,329,000	$5,540,000	$2,792,000	$1,033,000
Operating Expense	$20,085,000	$42,433,000	$38,072,000	$38,352,000
General And Administrative Expense	$5,795,000	$5,862,000	$5,942,000	$6,615,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-30,836,000	$-47,047,000	$-41,066,000	$-38,776,000
Net Interest Income	$-7,203,000	$-5,202,000	$-2,562,000	$-981,000
Interest Income	$126,000	$338,000	$230,000	$52,000
Normalized Income	$-27,288,000	$-47,635,000	$-40,634,000	$-39,333,000
Net Income From Continuing And Discontinued Operation	$-30,836,000	$-47,047,000	$-41,066,000	$-38,776,000
Total Operating Income As Reported	$-20,085,000	$-42,433,000	$-38,072,000	$-38,352,000
Net Income Common Stockholders	$-30,974,000	$-47,200,000	$-44,805,000	$-38,873,000
Net Income	$-30,836,000	$-47,047,000	$-41,066,000	$-38,776,000
Net Income Including Noncontrolling Interests	$-30,836,000	$-47,047,000	$-41,066,000	$-38,776,000
Net Income Continuous Operations	$-30,836,000	$-47,047,000	$-41,066,000	$-38,776,000
Pretax Income	$-30,836,000	$-47,047,000	$-41,066,000	$-38,776,000
Interest Income Non Operating	$126,000	$338,000	$230,000	$52,000
Operating Income	$-20,085,000	$-42,433,000	$-38,072,000	$-38,352,000
Per Share
Diluted EPS	$-0.48	$-0.76	$-0.74	$-0.65
Basic EPS	$-0.48	$-0.76	$-0.74	$-0.65
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-19,906,000	$-42,058,000	$-37,809,000	$-38,268,000
Total Unusual Items	$-3,548,000	$588,000	$-432,000	$557,000
Total Unusual Items Excluding Goodwill	$-3,548,000	$588,000	$-432,000	$557,000
Reconciled Depreciation	$53,000	$37,000	$33,000	$32,000
EBITDA (Bullshit earnings)	$-23,454,000	$-41,470,000	$-38,241,000	$-37,711,000
EBIT	$-23,507,000	$-41,507,000	$-38,274,000	$-37,743,000
Diluted Average Shares	$63,903,000	$62,309,000	$60,159,000	$59,391,000
Basic Average Shares	$63,903,000	$62,309,000	$60,159,000	$59,391,000
Diluted NI Availto Com Stockholders	$-30,974,000	$-47,200,000	$-44,805,000	$-38,873,000
Preferred Stock Dividends	$138,000	$153,000	$120,000	$97,000
Gain On Sale Of Security	$-3,548,000	$588,000	$-432,000	$557,000
Research And Development	$14,290,000	$36,571,000	$32,130,000	$31,737,000
Selling General And Administration	$5,795,000	$5,862,000	$5,942,000	$6,615,000
Other Gand A	$5,795,000	$5,862,000	$5,942,000	$6,615,000
Otherunder Preferred Stock Dividend	-	$0	$3,619,000	$0

Fetched: 2026-06-23

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-126,195,000	$-103,070,000	$-60,241,000	$-32,194,000
Total Assets	$19,532,000	$17,495,000	$28,200,000	$21,285,000
Total Non Current Assets	$96,000	$243,000	$490,000	$733,000
Other Non Current Assets	$96,000	$243,000	$490,000	$733,000
Current Assets	$19,436,000	$17,252,000	$27,710,000	$20,552,000
Other Current Assets	$1,716,000	$2,132,000	$2,050,000	$1,960,000
Cash Cash Equivalents And Short Term Investments	$17,720,000	$15,120,000	$25,660,000	$18,592,000
Cash And Cash Equivalents	$17,720,000	$15,120,000	$25,660,000	$18,592,000
Prepaid Assets	-	-	-	-
Debt
Net Debt	$116,015,000	$91,106,000	$46,081,000	$21,236,000
Total Debt	$133,757,000	$106,245,000	$71,787,000	$39,868,000
Long Term Debt And Capital Lease Obligation	$133,735,000	$85,109,000	$71,741,000	$39,828,000
Long Term Debt	$133,735,000	$85,109,000	$71,741,000	$39,828,000
Current Debt And Capital Lease Obligation	$22,000	$21,136,000	$46,000	$40,000
Current Debt	-	$21,117,000	-	-
Other Current Borrowings	-	$21,117,000	-	-
Liabilities
Total Liabilities Net Minority Interest	$145,727,000	$120,565,000	$88,441,000	$53,479,000
Total Non Current Liabilities Net Minority Interest	$137,697,000	$85,156,000	$72,765,000	$40,467,000
Derivative Product Liabilities	$3,962,000	$47,000	$1,004,000	$573,000
Current Liabilities	$8,030,000	$35,409,000	$15,676,000	$13,012,000
Payables And Accrued Expenses	$6,952,000	$12,381,000	$14,501,000	$11,999,000
Payables	$3,308,000	$5,719,000	$6,494,000	$3,954,000
Dividends Payable	$63,000	$63,000	$63,000	$64,000
Accounts Payable	$3,245,000	$5,656,000	$6,431,000	$3,890,000
Other Current Liabilities	-	$369,000	-	-
Other Non Current Liabilities	-	-	$20,000	$66,000
Equity
Common Stock Equity	$-128,408,000	$-105,293,000	$-62,464,000	$-34,427,000
Preferred Stock Equity	$2,213,000	$2,223,000	$2,223,000	$2,233,000
Total Equity Gross Minority Interest	$-126,195,000	$-103,070,000	$-60,241,000	$-32,194,000
Stockholders Equity	$-126,195,000	$-103,070,000	$-60,241,000	$-32,194,000
Retained Earnings	$-432,546,000	$-401,572,000	$-354,372,000	$-309,567,000
Other
Ordinary Shares Number	$65,201,995	$63,157,235	$61,852,914	$59,426,005
Share Issued	$65,201,995	$63,157,235	$61,852,914	$59,426,005
Tangible Book Value	$-128,408,000	$-105,293,000	$-62,464,000	$-34,427,000
Invested Capital	$5,327,000	$933,000	$9,277,000	$5,401,000
Working Capital	$11,406,000	$-18,157,000	$12,034,000	$7,540,000
Capital Lease Obligations	$22,000	$19,000	$46,000	$40,000
Total Capitalization	$7,540,000	$-17,961,000	$11,500,000	$7,634,000
Additional Paid In Capital	$304,073,000	$296,217,000	$291,847,000	$275,081,000
Capital Stock	$2,278,000	$2,285,000	$2,284,000	$2,292,000
Common Stock	$65,000	$62,000	$61,000	$59,000
Preferred Stock	$2,213,000	$2,223,000	$2,223,000	$2,233,000
Current Capital Lease Obligation	$22,000	$19,000	$46,000	$40,000
Pensionand Other Post Retirement Benefit Plans Current	$1,056,000	$1,523,000	$1,129,000	$973,000
Current Accrued Expenses	$3,644,000	$6,662,000	$8,007,000	$8,045,000
Net PPE	$0	$0	$0	$0
Accumulated Depreciation	$-74,000	$-74,000	$-74,000	$-74,000
Gross PPE	$74,000	$74,000	$74,000	$74,000
Leases	$2,000	$2,000	$2,000	$2,000
Machinery Furniture Equipment	$72,000	$72,000	$72,000	$72,000
Properties	$0	$0	$0	$0
Other Properties	-	-	-	$733,000

Fetched: 2026-06-23

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-23,875,000	$-41,767,000	$-32,965,000	$-31,056,000
Operating Activities
Operating Cash Flow	$-23,875,000	$-41,767,000	$-32,965,000	$-31,056,000
Cash Flow From Continuing Operating Activities	$-23,875,000	$-41,767,000	$-32,965,000	$-31,056,000
Operating Gains Losses	$3,546,000	$-588,000	$432,000	$-557,000
Investing Activities
Investing Cash Flow	$0	$0	$0	$0
Financing Activities
Issuance Of Capital Stock	$3,235,000	$0	-	$0
Financing Cash Flow	$26,475,000	$31,227,000	$40,033,000	$10,000,000
Cash Flow From Continuing Financing Activities	$26,475,000	$31,227,000	$40,033,000	$10,000,000
Net Common Stock Issuance	$3,235,000	$0	-	$0
Common Stock Issuance	$3,235,000	$0	-	$0
Other
Issuance Of Debt	$21,000,000	$30,000,000	$30,000,000	$10,000,000
End Cash Position	$17,720,000	$15,120,000	$25,660,000	$18,592,000
Beginning Cash Position	$15,120,000	$25,660,000	$18,592,000	$39,648,000
Changes In Cash	$2,600,000	$-10,540,000	$7,068,000	$-21,056,000
Proceeds From Stock Option Exercised	$2,240,000	$1,227,000	$10,033,000	$0
Net Issuance Payments Of Debt	$21,000,000	$30,000,000	$30,000,000	$10,000,000
Net Long Term Debt Issuance	$21,000,000	$30,000,000	$30,000,000	$10,000,000
Long Term Debt Issuance	$21,000,000	$30,000,000	$30,000,000	$10,000,000
Change In Working Capital	$609,000	$2,284,000	$4,678,000	$4,968,000
Change In Payables And Accrued Expense	$193,000	$2,366,000	$4,768,000	$4,867,000
Change In Accrued Expense	$6,235,000	$4,440,000	$2,097,000	$623,000
Change In Interest Payable	$6,235,000	$4,440,000	$2,097,000	$623,000
Change In Payable	$-6,042,000	$-2,074,000	$2,671,000	$4,244,000
Change In Account Payable	$-6,042,000	$-2,074,000	$2,671,000	$4,244,000
Change In Prepaid Assets	$416,000	$-82,000	$-90,000	$101,000
Other Non Cash Items	$1,094,000	$1,100,000	$697,000	$410,000
Stock Based Compensation	$1,659,000	$2,447,000	$2,261,000	$2,867,000
Depreciation Amortization Depletion	$53,000	$37,000	$33,000	$32,000
Depreciation And Amortization	$53,000	$37,000	$33,000	$32,000
Depreciation	$53,000	$37,000	$33,000	$32,000
Gain Loss On Investment Securities	$3,546,000	$-588,000	$432,000	$-557,000
Net Income From Continuing Operations	$-30,836,000	$-47,047,000	$-41,066,000	$-38,776,000

Fetched: 2026-06-23